DOI: 10.14704/nq.2018.16.8.1160

Intraperitoneal GABAB Receptor Antagonist (CGP 55845) Injections Moderately Affect the Behavior of Male Albino Mice

Sehrish Ashraf, Asia Perveen, Shahid Iqbal, Qurat Ul Annee Gillani, Furhan Iqbal

Abstract


In order to determine the effect of GABAB receptor antagonist, CGP 55845 {3-N [1-(S)-(3,4-dichlorophenyl)ethyl]amino-2-(S)-hydroxypropyl-P-benzyl-phosphinic acid} on the selective aspects of male albino mice behavior, present study was designed consisting of series of neurological (Rota rod, Open field, Morris Water Maze, Light and dark transition, Elevated plus maze and Novel object) tests. Mice were intraperitoneally injected with 1mg CGP 5584/ Kg body weight/ ml of Dimethyl Sulfoxide or with equal volume of saline solution (0.9 % NaCl) for twelve days. Data analysis for various parameters for rota rod, open field, light and dark transition test, elevated plus maze and novel object test revealed that the neuromuscular coordination, locomotory and exploratory behavior of male albino mice was not significantly affected by the CGP 55845 injections (P > 0.05). The results for Morris water maze (MWM) probe trial 1 indicated that CGP 55845 treated animals took less time and visited the platform area more frequently than controls indicating improved spatial memory but this affect were neutralized during probe trial 2 indicating that applied dose of CGP 55845 was unable to induce long term memory formation in male albino mice. We recommend further studies with higher dose concentration of CGP 55845 to explore its effect on albino male mice behavior.

Keywords


CGP 55845, GABAB Receptor Antagonist, Behavior, Morris Water Maze

Full Text:

PDF

References


Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABAB receptors. Physiological Reviews 2004; 84(3): 835-67.

Bischoff S, Leonhard S, Reymann N, Schuler V, Shigemoto R, Kaupmann K, Bettler B. Spatial distribution of GABABR1 receptor mRNA and binding sites in the rat brain. Journal of Comparative Neurology 1999; 412(1): 1-6.

Bormann J. The ‘ABC’of GABA receptors. Trends in Pharmacological Sciences 2000; 21(1): 16-19.

Bourin M, Hascoët M. The mouse light/dark box test. European Journal of Pharmacology 2003; 463(1-3): 55-65.

Bouwknecht JA, Paylor R. Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behavioural Brain Research 2002; 136(2): 489-501.

Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, Bonner TI, Enna SJ. International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acidB receptors: structure and function. Pharmacological Reviews 2002; 54(2): 247-64.

Chalifoux JR, Carter AG. GABAB receptor modulation of synaptic function. Current Opinion in Neurobiology 2011; 21(2): 339-44.

Chan KF, Burnham WM, Jia Z, Cortez MA, Snead III OC. GABAB receptor antagonism abolishes the learning impairments in rats with chronic atypical absence seizures. European Journal of Pharmacology 2006; 541(1-2): 64-72.

Couve A, Moss SJ, Pangalos MN. GABAB receptors: a new paradigm in G protein signaling. Molecular and Cellular Neuroscience 2000; 16(4): 296-312.

Cryan JF, Kaupmann K. Don't worry ‘B’happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences 2005;26(1):36-43.

Deisz RA, Billard JM, Zieglgänsberger W. Presynaptic and postsynaptic GABAB receptors of neocortical neurons of the rat in vitro: differences in pharmacology and ionic mechanisms. Synapse 1997; 25(1): 62-72.

Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112(2): 257-69.

Emson PC. GABAB receptors: structure and function. Progress in Brain Research 2007;160: 43-57.

Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, Mondadori CG, Pearlman R. SGS742: the first GABAB receptor antagonist in clinical trials. Biochemical Pharmacology 2004;68(8): 1479-87.

Froestl W, Mickel SJ, von Sprecher G, Diel PJ, Hall RG, Maier L, Strub D, Melillo V, Baumann PA. Phosphinic acid analogs of GABA. 2. Selective, orally active GABAB antagonists. Journal of Medicinal Chemistry 1995; 38(17): 3313-31.

Frostel W, Mickel S. Mondadori C, Olpe H, Bittiger H. GABAB receptors in memory process. Nucleic Aids 1992; 15: 30- 31.

Fukuda AT, Mody IS, Prince DA. Differential ontogenesis of presynaptic and postsynaptic GABAB inhibition in rat somatosensory cortex. Journal of Neurophysiology 1993; 70(1): 448-52.

Gillani Q, Ali M, Iqbal F. CGP 35348, GABAB receptor antagonist, has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage. BioMed Research İnternational 2014b; 2014.

Gillani Q, Iqbal S, Arfa F, Khakwani S, Akbar A, Ullah A, Ali M, Iqbal F. Effect of receptor antagonist (CGP35348) on learning and memory in albino mice. The Scientific World Journal 2014; 2014.

Heese K, Otten U, Mathivet P, Raiteri M, Marescaux C, Bernasconi R. GABAB receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology 2000; 39(3): 449-62.

Helm KA, Haberman RP, Dean SL, Hoyt EC, Melcher T, Lund PK, Gallagher M. GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacology 2005; 48(7): 956-64.

Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, Warsi SP, Waller JL, Terry AV. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. Journal of Pharmacology and Experimental Therapeutics 2006; 316(2): 679-94.

Hollis DM, Boyd SK. Distribution of GABA-like immunoreactive cell bodies in the brains of two amphibians, Rana catesbeiana and Xenopus laevis. Brain, Behavior and Evolution 2005; 65(2): 127-42.

Kandel E, Schwartz JH, Jessell TM. Principles of neural science. USA: McGraw-Hill Companies, 2000.

Kerr DI, Ong J. GABA agonists and antagonists. Medicinal Research Reviews 1992; 12(6): 593-636.

Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proceedings of the National Academy of Sciences 2004; 101(21): 8180-85.

Kleschevnikov AM, Belichenko PV, Mobley WC. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. Journal of Neuroscience 2012; 32(27): 9217-27.

Kulkarni SK. Animals behavioural models for testing anti-anxiety agents. In hand book of experimental pharmacology, 3rd edn. Delhi: Vallabh Prakashan, 2002: 27-37.

LaSarge CL, Montgomery KS, Tucker C, Slaton GS, Griffith WH, Setlow B, Bizon JL. Deficits across multiple cognitive domains in a subset of aged Fischer 344 rats. Neurobiology of Aging 2007; 28(6): 928-36.

Malcangio M, Ghelardini C, Giotti A, Malmberg‐Aiello P, Bartolini A. CGP 35348, a new GABAB antagonist, prevents antinociception and muscle‐relaxant effect induced by baclofen. British Journal of Pharmacology 1991; 103(2): 1303-08.

Meldrum BS, Chapman AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40: S2-6.

Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA B receptors in the modulation of anxiety-and antidepressant-like behavior. Neuropsychopharmacology 2004; 29(6): 1050-62.

Morishita R, Kato K, Asano T. GABAB receptors couple to G proteins Go, G∗o and Gi1 but not to Gi2. FEBS Letters 1990; 271(1-2): 231-35.

Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery 2011; 10(3): 209–19.

Olpe HR, Karlsson G, Pozza MF, Brugger F, Steinmann M, Van Riezen H, Fagg G, Hall RG, Froestl W, Bittiger H. CGP 35348: a centrally active blocker of GABAB receptors. European Journal of Pharmacology 1990; 187(1): 27-38.

Partyka A, Klodzinska A, Szewczyk B, Wieroñska JM, Chojnacka-Wójcik E, Librowski T, Filipek B, Nowak G, Pilc A. Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacological Reports 2007; 59(6): 757-62.

Pearl PL, Hartka TR, Cabalza JL, Taylor J, Gibson MK. Inherited disorders of GABA metabolism. Future of Neurology 2006; 1(5): 631-36.

Podhorna J, Brown RE. Strain differences in activity and emotionality do not account for differences in learning and memory performance between C57BL/6 and DBA/2 mice. Genes, Brain and Behavior 2002; 1(2): 96-110.

Richter MA, De Jesus DR, Hoppenbrouwers S, Daigle M, Deluce J, Ravindran LN, Fitzgerald PB, Daskalakis ZJ. Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder. Neuropsychopharmacology 2012; 37(5): 1144–51.

Rudolph U, Crestani F, Möhler H. GABAA receptor subtypes: dissecting their pharmacological functions. Trends in Pharmacological Sciences 2001; 22(4): 188-94.

Sherif FM. GABA-transaminase in brain and blood platelets: basic and clinical aspects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994; 18(8): 1219-33.

Zahra K, Khan MA, Iqbal F. Oral supplementation of Ocimum basilicum has the potential to improves the locomotory, exploratory, anxiolytic behavior and learning in adult male albino mice. Neurological Sciences 2015; 36(1): 73-78.

Zarrindast MR, Rostami P, Sadeghi-Hariri M. GABAA but not GABAB receptor stimulation induces antianxiety profile in rats. Pharmacology Biochemistry and Behavior 2001; 69(1-2): 9-15.


Supporting Agencies

Higher Education Commission (HEC) of Pakistan



| NeuroScience + QuantumPhysics> NeuroQuantology :: Copyright 2001-2018